343 related articles for article (PubMed ID: 8625991)
1. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.
Duchmann R; Schmitt E; Knolle P; Meyer zum Büschenfelde KH; Neurath M
Eur J Immunol; 1996 Apr; 26(4):934-8. PubMed ID: 8625991
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to interleukin 12 abrogate established experimental colitis in mice.
Neurath MF; Fuss I; Kelsall BL; Stüber E; Strober W
J Exp Med; 1995 Nov; 182(5):1281-90. PubMed ID: 7595199
[TBL] [Abstract][Full Text] [Related]
3. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance.
Elson CO; Beagley KW; Sharmanov AT; Fujihashi K; Kiyono H; Tennyson GS; Cong Y; Black CA; Ridwan BW; McGhee JR
J Immunol; 1996 Sep; 157(5):2174-85. PubMed ID: 8757344
[TBL] [Abstract][Full Text] [Related]
4. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice.
Zhao J; de Vera J; Narushima S; Beck EX; Palencia S; Shinkawa P; Kim KA; Liu Y; Levy MD; Berg DJ; Abo A; Funk WD
Gastroenterology; 2007 Apr; 132(4):1331-43. PubMed ID: 17408649
[TBL] [Abstract][Full Text] [Related]
5. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
6. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice.
Neurath MF; Fuss I; Pasparakis M; Alexopoulou L; Haralambous S; Meyer zum Büschenfelde KH; Strober W; Kollias G
Eur J Immunol; 1997 Jul; 27(7):1743-50. PubMed ID: 9247586
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.
Abad C; Martinez C; Juarranz MG; Arranz A; Leceta J; Delgado M; Gomariz RP
Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893
[TBL] [Abstract][Full Text] [Related]
8. Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model.
Van Montfrans C; Rodriguez Pena MS; Pronk I; Ten Kate FJ; Te Velde AA; Van Deventer SJ
Gastroenterology; 2002 Dec; 123(6):1865-76. PubMed ID: 12454844
[TBL] [Abstract][Full Text] [Related]
9. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis.
Guan Q; Ma Y; Hillman CL; Ma A; Zhou G; Qing G; Peng Z
Vaccine; 2009 Nov; 27(50):7096-104. PubMed ID: 19786142
[TBL] [Abstract][Full Text] [Related]
10. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.
Elinav E; Waks T; Eshhar Z
Gastroenterology; 2008 Jun; 134(7):2014-24. PubMed ID: 18424268
[TBL] [Abstract][Full Text] [Related]
11. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses.
González MA; Gonzalez-Rey E; Rico L; Büscher D; Delgado M
Gastroenterology; 2009 Mar; 136(3):978-89. PubMed ID: 19135996
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolérance: in vitro and in vivo considerations.
Drouault-Holowacz S; Foligné B; Dennin V; Goudercourt D; Terpend K; Burckel A; Pot B
Clin Nutr; 2006 Dec; 25(6):994-1003. PubMed ID: 16698150
[TBL] [Abstract][Full Text] [Related]
13. [Intestinal flora and Crohn's disease].
Desreumaux P; Colombel JF
Ann Pharm Fr; 2003 Jul; 61(4):276-81. PubMed ID: 12843962
[TBL] [Abstract][Full Text] [Related]
14. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.
Huibregtse IL; Snoeck V; de Creus A; Braat H; De Jong EC; Van Deventer SJ; Rottiers P
Gastroenterology; 2007 Aug; 133(2):517-28. PubMed ID: 17681173
[TBL] [Abstract][Full Text] [Related]
15. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acid-induced colitis in mice. Putative effect of antiinflammatory cytokines.
Gay J; Kokkotou E; O'Brien M; Pothoulakis C; Karalis KP
Neuroimmunomodulation; 2006; 13(2):114-21. PubMed ID: 17077645
[TBL] [Abstract][Full Text] [Related]
17. Oral tolerance to haptens: intestinal epithelial cells from 2,4-dinitrochlorobenzene-fed mice inhibit hapten-specific T cell activation in vitro.
Galliaerde V; Desvignes C; Peyron E; Kaiserlian D
Eur J Immunol; 1995 May; 25(5):1385-90. PubMed ID: 7774642
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of immune-mediated experimental colitis: tolerance induction in the presence of preexisting immunity and surrogate antigen bystander effect.
Gotsman I; Shlomai A; Alper R; Rabbani E; Engelhardt D; Ilan Y
J Pharmacol Exp Ther; 2001 Jun; 297(3):926-32. PubMed ID: 11356912
[TBL] [Abstract][Full Text] [Related]
19. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
20. IL-10 gene therapy prevents TNBS-induced colitis.
Lindsay J; Van Montfrans C; Brennan F; Van Deventer S; Drillenburg P; Hodgson H; Te Velde A; Sol Rodriguez Pena M
Gene Ther; 2002 Dec; 9(24):1715-21. PubMed ID: 12457286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
